Study Looks at Impact of Peritoneal Dialysis on Thyroid Function
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 23, 2024 -- Patients undergoing peritoneal dialysis (PD) have significantly higher thyroxine (T4) concentrations than hemodialysis (HD) patients and higher free T4 (FT4) concentrations at 12 and 24 months, according to a study published online Sept. 7 in Seminars in Dialysis.
Jelić Pranjić Ita, M.D., from the University Hospital Center Rijeka in Croatia, and colleagues conducted a prospective single-center study to examine thyroid function in 18 PD patients during a 24-month period. Data were compared to those from concurrently treated HD patients.
The researchers found that some of the PD patients had elevated thyroid-stimulating hormone levels initially, which normalized during follow-up, despite longer duration of dialysis. PD patients had significantly higher T4 concentrations at baseline and higher FT4 concentrations at 12 and 24 months compared with HD patients. At baseline and at 12 and 24 months, free triiodothyronine (FT3) levels were significantly higher; after the beginning of the study, T3 levels were within the reference interval. In PD patients, there was a positive association between T4 levels and 24-hour diuresis after 12 months.
"PD's continuous nature offers the benefit of better preservation of residual kidney function and gradual toxin removal," the authors write. "However, the complete precise factors influencing potential differences in survival have not been fully elucidated."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.